<DOC>
	<DOCNO>NCT00413634</DOCNO>
	<brief_summary>Age relate difference response drug could arise variation pharmacokinetic ( PK ) and/or pharmacodynamic ( PD ) profile age group . Whilst efficacy safety profile anagrelide well establish well-documented clinical trial programme patient age , formal study carry investigate whether PK profile anagrelide metabolite alter age . This study design allow comparison make term pharmacokinetics anagrelide metabolite elderly ( â‰¥ 65 year ) young ( 18-50 year ) ET patient</brief_summary>
	<brief_title>The Pharmacokinetics Anagrelide Elderly Young Patients With Essential Thrombocythaemia ( ET )</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<mesh_term>Anagrelide</mesh_term>
	<criteria>Young patient age 1850 year inclusive Elderly patient age 65 year Patients must confirm diagnosis ET . Currently receive anagrelide hydrochloride stable maintenance dose &lt; 5 mg/day least 4 week . Diagnosis myeloproliferative disorder . Current use tobacco form ( e.g . smoke chew ) Treatment know enzyme alter agent ( barbiturate , phenothiazine , cimetidine etc . ) within 30 day prior study . Patients use another cytoreductive agent addition anagrelide consider necessary control platelet count .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>